SUNSHINE
BIOPHARMA AND
UNIVERSITY OF GEORGIA TEAM UP
TO
DEVELOP A
NEW
ANTI-CORONAVIRUS
DRUG
Montreal, Canada -- October 19,
2020 -- InvestorsHub NewsWire -- Sunshine Biopharma Inc. (OTC
Markets:
"SBFM"), a pharmaceutical company focused on the research,
development and commercialization of oncology and antiviral
drugs today
announced that it has entered into an Agreement with the University of
Georgia for
the purposes of working together to advance
the development of Sunshine Biopharma's
recently
announced Anti-Coronavirus lead
compound,
SBFM-PL4. The goal of this
cutting-edge
collaboration is to
develop SBFM-PL4, a protease
inhibitor, as a treatment for Coronavirus infections.
This new
treatment is based on the technology
described in Sunshine
Biopharma's recently filed patent application
covering
small molecules
which can be used to treat Coronavirus infections.
Sunshine's
SBFM-PL4, will be put through a
series
of
in
vitro tests
to evaluate its specific inhibitory
activity against the SARS-CoV-2 papain-like
protease (PLpro), one of two
Coronavirus encoded proteases
essential for viral replication.
Following
the initial in
vitro studies, SBFM-PL4 will be moved forward to the
cell culture testing stage and assessment in Coronavirus
infected mice before entering human
clinical trials.
"We are delighted to
be
working with the University of Georgia
and Dr. Scott Pegan and his team of Coronavirus experts who share
our vision of developing a treatment that would make a difference
in the fight against the pandemic," said Dr. Steve Slilaty, CEO of
Sunshine Biopharma.
About
Sunshine Biopharma's Coronavirus Treatment
Severe Acute Respiratory
Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of
COVID-19, the current ongoing pandemic that has claimed the lives
of over 1,000,000 people worldwide since it
first appeared in December 2019. There are currently no drugs that
can effectively arrest replication of the virus in people who have
contracted the illness. On May 22, 2020, Sunshine Biopharma filed a
provisional patent application for a library of molecules which
were designed to inhibit the Coronavirus proteases, thus shutting
down the ability of the virus to multiply and cause
illness.
About the
University of Georgia
As part of its land grant
tripartite mission, the University of Georgia is committed to
creating and applying new knowledge for the public good.
UGA's Center for Drug Discovery as well as the Colleges of Pharmacy
are excited to be a part of this ground-breaking
research related to
discovery of new treatment options for COVID-19. Profs. Scott
Pegan, and David Crich will be working with Sunshine
Biopharma to spearhead the study of novel
therapeutics for the prevention and spread of COVID-19. This
interdisciplinary effort involves state of the art approaches in
chemical synthesis and drug screening. This continues
University of Georgia's long-standing tradition in translating
scientific breakthroughs to address real world health
concerns.
About
Sunshine Biopharma
In addition,
to working on the
development of a treatment for COVID-19, Sunshine Biopharma is engaged in the
development Adva-27a, a unique anticancer compound. Tests
conducted to
date have
demonstrated the effectiveness of Adva-27a at destroying Multidrug
Resistant Cancer Cells, including Pancreatic Cancer
cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and
Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer
indication are planned to be conducted at McGill University's
Jewish General Hospital in Montreal, Canada. Sunshine
Biopharma is owner of all patents and intellectual property
pertaining to Adva-27a.
Safe Harbor
Forward-Looking Statements
This
press release may contain forward looking statements which are
based on current expectations, forecasts, and assumptions that
involve risks as well as uncertainties that could cause actual
outcomes and results to differ materially from those anticipated or
expected, including statements related to the amount and timing of
expected revenues statements related to our financial performance,
expected income, distributions, and future growth for upcoming
quarterly and annual periods. These risks and uncertainties are
further defined in filings and reports by the Company with the U.S.
Securities and Exchange Commission (SEC).
Actual
results and the timing of certain events could differ materially
from those projected in or contemplated by the forward-looking
statements due to a number of factors detailed from time to time in
our filings with the SEC. Among other matters, the Company may not
be able to sustain growth or achieve profitability based upon many
factors including but not limited to general stock market
conditions. Reference is hereby made to cautionary statements set
forth in the Company's most recent SEC filings. We have incurred
and will continue to incur significant expenses in our expansion of
our existing as well as new service lines noting there is no
assurance that we will generate enough revenues to offset those
costs in both the near and long term.
Additional
service offerings may expose us to additional legal and regulatory
costs and unknown exposure(s) based upon the various geopolitical
locations we will be providing services in, the impact of which
cannot be predicted at this time.
For
Additional Information:
Sunshine
Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line:
514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com